Page 109 - Read Online

Di Nora et al. Vessel Plus 2022;6:46 https://dx.doi.org/10.20517/2574-1209.2021.126 Page 7 of 7

28. Ohiomoba RO, Youmans QR, Ezema A, et al. Cardiac transplantation outcomes in patients with amyloid cardiomyopathy. Am Heart J
2021;236:13-21. DOI PubMed
29. Di Nora C, Sponga S, Ferrara V, et al. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian
single-centre experience in heart transplantation. J Cardiovasc Med (Hagerstown) 2021;22:261-7. DOI PubMed
30. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain
amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18-22 April
2004. Am J Hematol 2005;79:319-28. DOI PubMed
31. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based
on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9. DOI PubMed
32. Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J
Heart Lung Transplant 2018;37:611-8. DOI PubMed
33. Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart
Fail 2021;23:895-905. DOI PubMed PMC
34. Obici L, Kuks JB, Buades J, et al; European Network for TTR-FAP (ATTReuNET). Recommendations for presymptomatic genetic
testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 2016;29 Suppl 1:S27-35.
DOI PubMed PMC
35. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European
society of cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail 2021;23:512-26. DOI PubMed
36. Davis MK, Lee PH, Witteles RM. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart
Lung Transplant 2015;34:658-66. DOI PubMed
37. Maurer MS, Schwartz JH, Gundapaneni B, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin
amyloid cardiomyopathy. N Engl J Med 2018;379:1007-16. DOI PubMed
38. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur
J Heart Fail 2020;22:39-53. DOI PubMed
39. Di Nora C, Miani D, D’Elia AV, et al. Heart transplantation in Danon disease: Long term single centre experience and review of the
literature. Eur J Med Genet 2020;63:103645. DOI PubMed
40. Di Nora C, Paldino A, Miani D, et al. Heart transplantation in kearns-sayre syndrome. Transplantation 2019;103:e393-4. DOI
PubMed
41. Di Nora C, Livi U. Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis. Curr Opin Organ
Transplant 2020;25:211-7. DOI PubMed
42. Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis
complicated by heart failure. Transplantation 2007;83:539-45. DOI PubMed
43. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience.
J Heart Lung Transplant 2004;23:1142-53. DOI PubMed
44. Grogan M, Gertz M, McCurdy A, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the
Mayo clinic experience. World J Transplant 2016;6:380-8. DOI PubMed PMC
45. Barrett CD, Alexander KM, Zhao H, et al. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC
Heart Fail 2020;8:461-8. DOI PubMed
46. Mignot A, Varnous S, Redonnet M, et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French
patients. Arch Cardiovasc Dis 2008;101:523-32. DOI PubMed